Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational

Steffen Weber-Carstens1, Maria Deja, Susanne Koch

  • 1Clinic of Anesthesiology and Intensive Care Medicine, Charité University Medicine, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. steffen.weber-carstens@charite.de

Insights

Systemic inflammation is the primary risk factor for critical illness myopathy (CIM) in intensive care unit (ICU) patients. Early identification of inflammation can help predict and potentially prevent CIM development.

Area of Science:

  • Critical care medicine
  • Neuromuscular disorders
  • Intensive care unit (ICU) research

Background:

  • Non-excitable muscle membrane is a hallmark of critical illness myopathy (CIM) during early stages of critical illness.
  • Understanding predisposing risk factors for CIM is crucial for timely intervention and improved patient outcomes.

Purpose of the Study:

  • To investigate predisposing risk factors for the development of non-excitable muscle membrane in intensive care unit (ICU) patients.
  • To identify key clinical and biological markers associated with early-onset CIM.

Main Methods:

  • Sequential measurements of muscle membrane excitability using direct muscle stimulation (dmCMAP) in 40 ICU patients.
  • Analysis of risk factors including the insulin-like growth factor (IGF)-system, inflammatory markers, metabolic and hemodynamic parameters, and medical treatments.
  • Utilized nonparametric analysis of longitudinal data and multivariate Cox regression for statistical analysis.

Main Results:

  • 22 patients (55%) exhibited abnormal muscle membrane excitability within 7 days of ICU admission.
  • Univariate analysis identified inflammation, disease severity, catecholamine/sedation use, and IGF binding protein-1 (IGFBP-I) as significant risk factors.
  • Multivariate analysis revealed interleukin-6 (IL-6) as the sole significant predictor of impaired muscle membrane excitability (HR 1.006, P = 0.002).

Conclusions:

  • Systemic inflammation in early critical illness is the principal risk factor for developing CIM.
  • Inflammation-induced impairment of growth-factor mediated insulin sensitivity may contribute to CIM pathogenesis.
Abstract

Related Concept Videos

Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...